Zenas Biopharma opened lower at $28.18, compared with its previous close of $28.70. In the last trading session, the stock traded between $27.42 and $28.75. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Zenas Biopharma is now worth
$ 152.40
Giving a profit of
$ 52.40 (52.40%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-1.04 (-3.62%)
Day High
$28.75
Day Low
$27.42
Day Open
$28.18
Prev Close
$28.70
Volume
7,20,580
1W Return
-2.63%
1M Return
4.79%
3M Return
-14.84%
6M Return
35.59%
1Y Return
-21.42%
Market Cap ($ Mn)
1,876
PE Ratio
-
PB Ratio
8.00
PEG Ratio
-
ROE
-148.14%
ROCE
-134.00%
EPS (TTM)
$-1.61
1 Week
-2.63%
1 Month
4.79%
3 Months
-14.84%
6 Months
35.59%
9 Months
18.87%
Zenas BioPharma reports 93% flare-free rate in IgG4-RD trial
Phase 3 INDIGO open-label extension showed 0.93 probability of remaining flare-free at 12 months based on adjudicated data. Obexelimab reduced cumulative glucocorticoid toxicity versus placebo with a GTI score difference of -11.4 (p=0.021). Vaccine sub-study reported 86% seroimmunity to influenza and 100% to COVID-19 during treatment-free windows. Median cumulative glucocorticoid rescue dose was 0 mg, indicating minimal need for steroid intervention.
1mo agoZenas BioPharma to host virtual R&D event on Oct 27
Zenas BioPharma will host a virtual R&D event on October 27, 2026. Management will present updates on obexelimab and ZB021 pipeline candidates. Dr. Joseph F. Merola will provide clinical insights on autoimmune biology.
1mo agoZenas to present obexelimab Phase 3 data at IgG4-RD symposium and ACR
Zenas BioPharma to present obexelimab data at IgG4-RD Symposium and ACR Convergence 2026. Key presentations include longer-term flare protection and safety from Phase 3 INDIGO open-label extension. Additional analyses cover glucocorticoid-associated toxicity and vaccine responses. Obexelimab evaluated in nine trials involving 667 subjects.
1mo agoZenas BioPharma grants 53,700 stock options to new employees
Zenas BioPharma granted 53,700 stock options and 98,900 RSUs to new hires. Stock options have an exercise price of $31.93 and a ten-year term. Awards vest over four years contingent on continued employee service. Grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement.
1mo agoZenas BioPharma registers resale of 7M shares by InnoCare Pharma
Zenas BioPharma files Form S-3ASR for resale of 7,000,000 shares. InnoCare Pharma Inc. is the designated selling stockholder. Shares acquired via subscription agreement dated October 7, 2025. Transaction was exempt from registration under Securities Act Section 4(a)(2).
2mo agoZenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Zenas BioPharma hosts virtual investor event on Sept 29, 2026. Focus on obexelimab for IgG4-RD and prelaunch strategies. FDA accepted BLA in Aug 2026 with PDUFA date of May 27, 2027. EMA submission expected in second half of 2026.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Zenas Biopharma is now worth
$ 152.40
Giving a profit of
$ 52.40 (52.40%)
Note: Past profits do not guarantee future returns.
